Create Free Account

By creating account you will get access to hot stocks & personalised emails

Clinuvel Pharmaceuticals Ltd

Healthcare AU CUV

14.86AUD
-0.2(1.33%)

Last update at 2024-05-02T06:10:00Z

Day Range

14.8315.10
LowHigh

52 Week Range

12.9621.40
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 45.58M 34.32M 25.71M 13.14M 18.11M
Minority interest - - - - -
Net income 30.60M 20.88M 24.73M 16.65M 16.65M
Selling general administrative 22.57M 17.71M 12.76M 1.15M 8.93M
Selling and marketing expenses - - - 1.89M 1.50M
Gross profit 69.53M 55.24M 43.26M 22.94M 24.18M
Reconciled depreciation 0.79M 0.76M 0.86M 0.43M 0.21M
Ebit 48.77M 36.60M 27.33M 13.16M 18.14M
Ebitda 49.56M 37.35M 28.19M 13.59M 18.35M
Depreciation and amortization 0.79M 0.76M 0.86M 0.43M 0.21M
Non operating income net other - - - - -
Operating income 44.13M 35.55M 28.57M 12.25M 18.14M
Other operating expenses -18.41361M -11.06945M -12.64121M -4.93204M 14.57M
Interest expense 3.19M 2.27M 1.62M 0.03M 0.02M
Tax provision 14.97M 13.44M 0.98M -3.51039M -0.01933M
Interest income 2.45M 0.44M 0.34M 0.63M 0.86M
Net interest income 0.71M -1.83029M -1.27623M -0.02589M 0.54M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 14.97M 13.44M 0.98M -3.51039M -0.01933M
Total revenue 78.32M 65.72M 47.98M 32.57M 31.05M
Total operating expenses 25.43M 19.91M 15.03M 11.55M 7.70M
Cost of revenue 8.79M 10.48M 4.72M 9.63M 6.87M
Total other income expense net 0.76M 0.82M -1.23556M 0.78M -0.02111M
Discontinued operations - - - - -
Net income from continuing ops 30.60M 20.88M 24.73M 16.65M 18.13M
Net income applicable to common shares 30.60M 20.88M 24.73M 16.65M 18.13M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 193.71M 143.95M 108.57M 81.54M 62.35M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.07M 1.04M 0.88M 0.51M 0.59M
Total liab 29.08M 18.39M 9.83M 7.87M 5.17M
Total stockholder equity 164.63M 125.56M 98.74M 73.67M 57.18M
Deferred long term liab - - - - -
Other current liab 22.70M 13.47M 4.05M 6.83M 3.20M
Common stock 151.85M 151.85M 151.85M 151.85M 151.31M
Capital stock 151.85M 151.85M 151.85M 151.85M 151.31M
Retained earnings -9.77428M -38.40243M -58.12977M -80.03729M -95.48674M
Other liab 2.89M 3.72M 0.08M 0.11M 0.03M
Good will 0.19M 0.19M 0.19M 0.19M 0.19M
Other assets 1.06M 0.48M 2.93M 3.81M 0.30M
Cash 156.81M 121.51M 82.69M 66.75M 54.27M
Cash and equivalents - - - - -
Total current liabilities 25.49M 13.73M 8.71M 6.66M 4.96M
Current deferred revenue -0.30084M -0.31507M 2.07M -1.81407M -
Net debt -155.81367M -120.25275M -81.38751M -65.42697M -53.83624M
Short term debt 0.30M 0.32M 0.26M 0.21M 0.26M
Short long term debt - - - - -
Short long term debt total 1.00M 1.26M 1.30M 1.32M 0.43M
Other stockholder equity -142.07510M -113.44695M -93.71961M -70.21643M 1.35M
Property plant equipment 2.85M 2.70M 2.60M 2.39M 0.71M
Total current assets 189.62M 140.58M 102.85M 75.16M 61.15M
Long term investments - - - - -
Net tangible assets 164.45M 125.37M 98.55M 73.48M 56.99M
Short term investments 133.93M 98.66M 48.12M 42.87M 29.83M
Net receivables 22.21M 16.20M 16.09M 6.61M 4.16M
Long term debt - - - - -
Inventory 9.52M 1.83M 3.19M 1.29M 2.14M
Accounts payable 2.79M 0.26M 2.32M 1.43M 1.50M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 22.56M 12.11M 5.02M 1.86M 1.35M
Additional paid in capital - - - - -
Common stock total equity - - - 151.85M 151.31M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -3.03622M -2.88537M -2.78817M -2.57441M 1.19M
Deferred long term asset charges - - - - -
Non current assets total 4.10M 3.37M 5.72M 6.39M 1.19M
Capital lease obligations 1.00M 1.26M 1.30M 1.32M 0.43M
Long term debt total 0.70M 0.94M 1.05M 1.11M 0.17M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -1.02753M -0.43444M -0.85433M -0.88883M -0.25762M
Change to liabilities 3.08M 6.06M 0.86M -2.44473M 1.49M
Total cashflows from investing activities -1.02753M -0.43444M -0.85433M -0.88883M -0.25762M
Net borrowings -0.26372M -0.26849M -0.20028M -0.24334M -0.06963M
Total cash from financing activities -2.24013M -1.50376M -1.47995M -1.48586M -1.03067M
Change to operating activities -1.41079M -2.53498M -0.02215M 0.77M -0.14145M
Net income 30.60M 20.88M 24.73M 15.05M 18.13M
Change in cash 35.30M 38.82M 15.94M 12.48M 18.07M
Begin period cash flow 121.51M 82.69M 66.75M 54.27M 36.20M
End period cash flow 156.81M 121.51M 82.69M 66.75M 54.27M
Total cash from operating activities 36.91M 39.87M 19.26M 14.19M 18.46M
Issuance of capital stock - - - - -
Depreciation 0.74M 0.72M 0.82M 0.43M 0.21M
Other cashflows from investing activities - - - - -
Dividends paid -1.97641M -1.23527M -1.23527M -1.22402M 0.96M
Change to inventory -7.68757M 1.35M -1.89876M 0.85M -1.49480M
Change to account receivables -6.01271M -0.11341M -9.47584M -2.45647M 0.93M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.26372M -0.26849M -0.24469M -0.24334M -0.25762M
Change to netincome 8.78M 6.32M 4.25M 0.40M -0.68253M
Capital expenditures 1.03M 0.43M 0.85M 0.89M 0.26M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -13.70028M 1.24M -11.37460M -1.60830M 0.44M
Stock based compensation 8.99M 6.12M 2.60M 1.66M -
Other non cash items 5.57M 18.28M -6.28577M -1.29046M -18.34832M
Free cash flow 35.88M 39.44M 18.41M 13.30M 18.20M

Fundamentals

  • Previous Close 15.06
  • Market Cap767.95M
  • Volume57009
  • P/E Ratio26.88
  • Dividend Yield0.34%
  • EBITDA44.36M
  • Revenue TTM81.76M
  • Revenue Per Share TTM1.65
  • Gross Profit TTM 70.80M
  • Diluted EPS TTM0.57

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CUV
Clinuvel Pharmaceuticals Ltd		 -0.2 1.33% 14.86 26.88 18.35 9.26 4.24 7.18 11.51
CSL
CSL Ltd		 0.90 0.33% 275.39 35.08 31.35 9.60 5.16 10.91 34.93
TLX
Telix Pharmaceuticals Ltd		 0.13 0.89% 14.80 763.75 21.01 8.47 28.69 8.21 177.65
NEU
Neuren Pharmaceuticals Ltd		 0.12 0.63% 19.18 16.04 38.46 11.63 13.15 10.65 12.39
MSB
Mesoblast Ltd		 -0.03 2.73% 1.07 - 769.23 116.88 1.12 126.11 -19.3368

Reports Covered

Stock Research & News

View All

Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Clinuvel Pharmaceuticals Ltd

535 Bourke Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Philippe Jacques Wolgen M.B.A., M.D., MBA CEO, MD & Director 1963
Mr. Darren M. Keamy CFO & Company Sec. 1973
Dr. Dennis J. Wright Chief Scientific Officer NA
Mr. Lachlan Hay Director of Global Operations NA
Mr. Malcolm Bull Head of Investor Relations NA
Dr. Philippe Jacques Wolgen M.B.A., M.D. CEO, MD & Director 1963
Mr. Darren Michael Keamy B.Com., CPA CFO & Company Secretary 1973
Mr. Malcolm Bull Head of Australian Operations & Investor Relations NA
Dr. Rose Quadbeck-Diel Senior Vice President of Regulatory Affairs NA
Dr. Azza Hamila Head of Quality & Drug Safety NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.